Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorolanib +/- Toripalimab in Adjuvant RCC
NCT07047001Phase 2Active, not recruiting
- Sponsor
- Dongwen Biopharmaceutical
- Start
- Apr 2025
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vorolanib in renal cell carcinoma (RCC) (2 arms), sponsored by Dongwen Biopharmaceutical. Primary endpoint: 2-year Disease-Free Survival. Started Apr 2025; status: active, not recruiting.
02
Drugs
vorolanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07047001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07047001.